3 Min Read
ZURICH, Oct 3(Reuters) - The Swiss blue-chip SMI was seen opening almost unchanged at 8,142 points on Monday, according to premarket indications by bank Julius Baer .
The following are some of the main factors expected to affect Swiss stocks:
Novartis's psoriasis drug Cosentyx showed long-term efficacy in keeping patients' skin clear, the Swiss drugmaker said on Saturday, citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson.
Novartis also presented findings from global survey to date of people with psoriasis, which showed many do not achieve the treatment goal of clear skin or even believe it is a realistic goal.
For more news, click on
China's HNA Group, which owns Swissport, Gategroup and SR Technics, is looking for further buys in Switzerland, its CEO told Finanz und Wirtschaft.
For more news, click on
* Roche said first phase III data on TECENTRIQ (atezolizumab) will feature at the 2016 European Society for Medical Oncology (ESMO) Congress.
* SGS announced the acquisition of Roos+Bijl, headquartered in Rhoon, the Netherlands. The company is expected to generate 2016 revenues in excess of 7 million euros, SGS said. SGS also said it is investing in a new facility in Berlin to expand its R&D/QC testing activities, and to offer new analytical services to clients.
* Schindler Holding said it has completed the sale of its operations in Japan to Otis Japan.
* Clariant said it will exhibit at CPhI Worldwide 2016 to show pharmaceutical professionals new ways to protect products and ensure access to safe medicines for patients.
* Accu Holding reported a first half net loss of 21.1 million Swiss francs. The company's suspension from the Swiss stock exchange was lifted after the publication of the results.
* Datwyler said it has completed the completion of technology and materials company Ott.
* Temenos said "a major European bank" had selected UniversalSuite, its front-to-back solution for retail, commercial and corporate banking.
* Tecan said it had successfully completed the acquisition of SPEware Corporation.
* HBM Healthcare Investments said it terminated its share buy-back programme 2014
* Ascom said its divestment of the Network Testing Division to InfoVista was successfully closed on Sept. 30. Ascom said it was "now a one business company" focused on healthcare ICT and mobile workflow solutions.
* Airopack posted a net loss of 16.2 million euros for the first half of 2016.
* USI Group Holdings said it expects its merger with RP&C International to occur this week, once all regulatory approvals have been obtained.
* SE Swiss Estates said first-half net profit was 488,000 francs, compared to 367,000 francs in the previous year.
* Swiss retail sales data for August is due to be released at 0715 GMT.
* Manufacturing Purchase Managers Index is due to be released at 0730 GMT.
* The Swiss National Bank releases sight deposits data at 0800 GMT.
Reporting by Zurich newsroom